Glomerulonephritis, Postinfectious

Glomerulonephritis, Postinfectious is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

5-Minute Clinical Consult (5MCC) app and website powered by Unbound Medicine helps you diagnose and manage 900+ medical conditions. Exclusive bonus features include Diagnosaurus DDx, 200 pediatrics topics, and medical news feeds. Explore these free sample topics:

5-Minute Clinical Consult

-- The first section of this topic is shown below --



Postinfectious glomerulonephritis (PIGN) is an immune complex disease associated with nonrenal infection by certain strains of bacteria, most commonly Streptococcus and Staphylococcus. The most common form of PIGN, poststreptococcal glomerulonephritis (PSGN), is preceded by Streptococcus and predominantly affects children. The clinical presentation varies from asymptomatic to the acute nephritic syndrome, characterized by gross hematuria, proteinuria, edema, hypertension (HTN), and acute kidney injury.


A global decline in incidence, especially in developed countries, is attributed to better hygiene and a decreased incidence of streptococcal skin infections. Of cases, 97% occur in developing countries. PSGN is primarily a pediatric disease, but a recent increase has been seen in nonstreptococcal GN in adults.

  • Pediatrics: 24.3 cases/100,000 persons per year in developing countries; 6 cases/100,000 persons per year in developed countries
  • Adults: 2 cases/100,000 persons per year in developing countries; 0.3 cases/100,000 persons per year in developed countries
  • Worldwide: 34% of cases are now seen in adults with a global burden of 68,000 cases per year.
  • Male > female (2:1) (1)

Etiology and Pathophysiology

  • Glomerular immune complex disease induced by specific nephritogenic strains of bacteria:
    • Group A β-hemolytic Streptococcus (GAS)
    • Staphylococcus (predominantly Staphylococcus aureus; more commonly methicillin-resistant S. aureus [MRSA], occasionally coagulase-negative Staphylococcus)
    • Gram-negative bacteria, including Escherichia coli, Yersinia, Pseudomonas, and Haemophilus (1)
  • Proposed mechanisms for the glomerular injury (2):
    • Deposition of circulating immune complexes with streptococcal or staphylococcal antigens—these complexes can be detected in patients with streptococcal- or staphylococcal-related GN but do not correlate to disease activity (3).
    • Note: IgG is the most frequent immunoglobulin in PSGN (1).
    • In situ immune complex formation from deposition of antigens within the glomerular basement membrane (GBM) and subsequent antibody binding
    • In situ glomerular immune complex formation promoted by antibodies to streptococcal or staphylococcal antigens
    • Alteration of normal renal antigen leading to molecular mimicry that elicits an autoimmune response
  • Glomerular immune complex causing complement activation and inflammation:
    • Nephritis-associated plasmin receptor (NAPlr): activates plasmin, contributes to activation of the alternative complement pathway
    • Streptococcal pyrogenic exotoxin B (SPE B): binds plasmin and acts as a protease; promotes the release of inflammatory mediators
  • Activation of the alternative complement pathway causes initial glomerular injury as evidenced by C3 deposition and decreased levels of serum C3. The lectin pathway of complement activation has also been recently implicated in glomerular injury (4).

Risk Factors

  • Children 5 to 12 years of age
  • Older patients (>65 years of age) (1):
    • Patients with immunocompromising comorbid conditions
    • Diabetes
    • Alcohol abuse

General Prevention

  • Early antibiotic treatment for streptococcal and staphylococcal infections, when indicated, although efficacy in preventing GN is uncertain
  • Improved hygiene
  • Prophylactic penicillin treatment to be used in closed communities and household contacts of index cases in areas where PIGN is prevalent

Commonly Associated Conditions

Commonly streptococcal or staphylococcal infection

-- To view the remaining sections of this topic, please or purchase a subscription --